Allogenic immune cell therapies to be developed as three groups join forces
Three entities have joined forces to develop allogenic immune cell therapies based on a platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs).
ElevateBio LLC is a technology-driven company focused on powering transformative cell and gene therapies. It announced recently (August 5) that it has formed a yet-to-be-named company co-founded by Harvard Medical School Dean, George Daley and Boston Children’s Hospital to develop the cell therapies.
This proprietary differentiation process overcomes the tendency of iPSCs to generate immature, embryonic blood cell types, and enables the generation of multiple subtypes of immune cells that display mature molecular signatures similar to T cells from adult blood.
The peer-reviewed publication in the journal Cell Stem Cell showed that iPSC-derived mature αβ T cells exhibited antitumor activity and cytokine secretion and could serve as an ideal source for the development of allogeneic off-the-shelf therapies.
CEO of ElevateBio, said: “We have been rapidly building fully integrated end-to-end cell and gene therapy enabling technologies and capabilities to enable the world’s most prolific scientific innovators and visionaries, such as Dr. Daley, to push the boundaries of the field and deliver powerful new therapeutic modalities for patients.
“This exciting new company is the first from our collaboration with Boston Children’s Hospital and is a prime example of how our integrated ecosystem – our iPSC cell lines and process development capabilities, our gene editing technology, our CAR and TCR constructs, and our scale-up manufacturing capabilities – creates the perfect foundation needed to turn these scientific breakthroughs into transformational medicines.”
منبع:
https://www.labiotech.eu/trends-news/allogenic-immune-cell-therapies-developed-three-become-one
ارسال به دوستان